<DOC>
	<DOC>NCT00776659</DOC>
	<brief_summary>To generate the following data from patients with early breast cancer treated with Aromasin速 in the adjuvant setting in India. - Efficacy of the treatment with Aromasin速 - Safety of the treatment with Aromasin速</brief_summary>
	<brief_title>An Observational Study Of Indian Breast Cancer Patients Receiving Adjuvant Therapy With Aromasin</brief_title>
	<detailed_description>NA The study was prematurely discontinued due to slow enrollment and keeping in mind the observational nature of the study. The decision to terminate had been taken on 16th June 2012 and the LSLV occured on 14th September, 2012. It should be noted that safety concerns have not been seen in this study and have not factored into this decision.</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Exemestane</mesh_term>
	<criteria>Patients with early breast cancer receiving adjuvant therapy with Aromasin速 will be eligible. Patients presenting with in situ cancers, recurrent or metastatic breast cancer, or a 2nd primary will not be included. Patients with a known hypersensitivity to Exemestane or its metabolites will also not be included.</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>September 2013</verification_date>
	<keyword>An Observational Study of Indian Breast Cancer Patients Receiving Adjuvant Therapy with Aromasin</keyword>
	<keyword>Antineoplastic Hormonal Drugs</keyword>
	<keyword>Aromasin</keyword>
</DOC>